FIRST

Follow-up In Rivaroxaban patients in Setting of Thromboembolism (FIRST)

The FIRST registry is a prospective, non-interventional, single cohort multicenter study registered with the NIHR CRN portfolio.  The study is led by King’s College Hospital in London and is funded by Bayer.   

The study is investigating the incidence of long-term complications of VTE recurrence, post-thrombotic syndrome (PTS) and chronic thromboembolic pulmonary hypertension (CTEPH) for VTE patients treated with rivaroxaban without bridging heparin. No additional visits are required other than the routine clinical practice of the treating hospital or GP practice. 

We are also investigating, as secondary objectives, treatment adherence and satisfaction, long-term treatment emergent bleeding rates, all-cause mortality, healthcare resource utilisation, route cause analysis of major bleeding and recurrent VTE events, and long-term incidence of other thromboembolic complications.

HaemSTAR lead: Dr Zara Sayar

The FIRST registry is now closed, having recruited more than one thousand patients. The project is now in the follow-up phase and this page will be updated when results are published.

Lay Summary

The FIRST audit followed people with blood clots (VTE) who were treated with rivaroxaban to see how they did over time. It looked at how often serious long-term problems happened, such as repeat clots, long-term leg problems, or lung complications. The audit did not change patients’ normal care and required no extra clinic visits. Over 1,000 patients were enrolled, and the audit is now finished and waiting for results to be published.